Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 4/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
| ▸ | NPPA | P01160 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9880273 | 0.80 | S1PR1 (0.50) | ENPP3ENPP1RAB9ASMN1; SMN2AKR1B1 | |
| SCHEMBL8334940 | 0.77 | S1PR1 (0.53) | ENPP3ENPP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4150532 | 0.77 | ALDH1A1 (0.46) | ENPP3ENPP1RAB9ASMN1; SMN2AKR1B1 | |
| SCHEMBL201772 | 0.77 | AKR1B1 (0.43) | ENPP3ENPP1RAB9ASMN1; SMN2AKR1B1 | |
| SCHEMBL28956300 | 0.77 | NOTUM (0.46) | ENPP3ENPP1RAB9AAKR1B1HSD11B1 | |
| SCHEMBL4142338 | 0.77 | NOTUM (0.49) | ENPP3ENPP1RAB9AAKR1B1HSD11B1 | |
| SCHEMBL6594295 | 0.77 | AKR1B1 (0.49) | ENPP3ENPP1RAB9AAKR1B1HSD11B1 | |
| SCHEMBL12064815 | 0.74 | NPC1 (0.51) | ENPP3ENPP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1272971 | 0.73 | HSD11B1 (0.47) | ENPP3ENPP1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL24702058 | 0.73 | LMNA (0.37) | RAB9ANPC1HTTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| WO-2021222483-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | ENPP3 349/4885ENPP1 208/4885RAB9A 2710/4885 |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | ENPP3 353/4885ENPP1 228/4885RAB9A 2831/4885 |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | ENPP3 353/4885ENPP1 228/4885RAB9A 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.